BCEIE › SUNPHARMA
Sun Pharmaceutical Industries Limited
Latest filings
- Routine15
- Routine15
- Routine15
- Routine15
- General30
- Routine15Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
- Routine15
- Routine15
- Routine15
- Routine15
News
- Sun Pharmaceutical Industries: Unaudited Financial Results for the quarter and half year ended 30 September 2026
- Sun Pharmaceutical Industries: ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharmaceutical Industries allots ₹7,816 crore non-convertible debentures (NCDs)
- Sun Pharmaceutical Industries Independent Director Gautam Doshi Mr. Gautam resigns
- Sun Pharmaceutical Industries: A press release for Lerodalcibep licensing agreement